

\	\tilde{E}^{I}			_				
	TRADEMENT		TECH CENTER 1600	网				
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE								
Applicant:	Charles A. Nicolette			EST.				
Filing Date:	August 17, 2001	Examiner:	Not Yet Assigned	D D				
Serial No.:	09/931, 969	Group Art U	nit: 1614	, 200				
Title:	THERAPEUTIC COMPOUR	NDS FOR OVARIAN CAN	ICER &	CENTER 1800/2002				
Box IDS Commissione Washington,								
	SUPPLEMENTAL INFORM	ATION DISCLOSURE ST	ATEMENT					
Sir:								
	In accordance with 37 C.F.R. e being brought to the attention nination of the above-identified	of the Examiner for consid		1				
I. Timing of	the Information Disclosure S	Statement:						
This Informat	tion Disclosure Statement is fil	ed:						
	With the new patent applicat	ion submitted herewith (37	C.F.R. § 1.97(a)).					
	Within three months after the after the date of entry of the 137 C.F.R. § 1.491.			ıths				
	Before the mailing date of a however, that an Office Action Disclosure Statement, the Condensit Account No. 50-118 37 C.F.R. §§ 1.17(p) or 1.176	on has crossed in the mail volumissioner is hereby authors for any fees required purs	vith this Information orized to charge					
This Informat	tion Disclosure Statement is fil	led:						
	After the first Office Action a filing date; or PCT national sundersigned prior to the mai	stage date of entry filing but	, as far as is known to					

allowance, whichever occurs first, and the Commissioner is hereby authorized to

charge Deposit Account No.[] for the fee (\$180) set forth in

37 C.F.R. § 1.17(p) and any additional required fees.

This Informa	tion Disclosure Statement is filed:		
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.		
The undersig	ned certifies that:		
	Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.		
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
II. Copies of	f the Cited Items:		
\boxtimes	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.		
	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:		
	Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No, filed and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).		
	Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.		
III. Concise	Explanation of Relevance:		
\boxtimes	A concise explanation of relevance of the items listed on Form PTO-1449 is not given.		
	A concise explanation of relevance of [some of] the items listed on Form PTO- 1449 is in the form of an English language copy of a Search Report from a foreign		

patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).

IV. Related Applications:

 \boxtimes Applicants bring to the Office's attention the following related, co-pending application(s): U.S. Serial No.: 10/079,699, filed February 19, 2002 and PCT Application Nos. PCT/US01/25708 and PCT/US02/05322, filed August 17, 2001, and February 19, 2002, respectively.

V. Conclusion:

Citation of the above documents shall not be construed as:

- an admission that the documents are necessarily prior art with respect to the 1. instant invention;
- a representation that a search has been made, other than as described above; or 2.
- an admission that the information cited herein is, or is considered to be, material 3. to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189 billing reference number: 19442-7235 for any additional fees required in connection with the filing of this Information Disclosure Statement.

DATE: April 2, 2002

Respectfully submitted.

Antoinette F. Konski

Registration No.: 34,202

McCutchen, Doyle, Brown & Enersen, LLP Three Embarcadero Center, Suite 1800 San Francisco, California 94111

Telephone: (650) 849-4950 Telefax: (650) 849-4800

PTO/SB/08 (2/92)

Sheet 1 of 1 Form PTO-1449 Docket No. GZ 2104.00 Applicant(s) Charles A. NICOLETTEAPR 1 7 2002 INFORMATION DISCLOSURE **STATEMENT** TEGH GENTER 14600/2900 Filing Date: August 17, 2001 (use several sheets if necessary) U.S. PATENT DOCUMENTS Class Ref. Date Document No. Subclass Filing Date Examiner Name (if appropriate) Initials No. FOREIGN PATENT DOCUMENTS Date Translation Ref. Document No. Class **Subclass** Examiner Name Initials No. YES NO EP 0 702 082 A1 3/20/96 Hagiware, et al. /1. OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Examiner Ref. Title Initials No. Colona, Marco, et al., (1995) "Cloning of Immunoglobulin-Superfamily Members Associated with HLA-C 2. and HLA-B Recognition by Human Natural Killer Cells" Science, 268:405-408. 3. Cockle, S.M., et al., (1989) "Thyrotrophin-releasing hormone-related polypeptides in rabbit prostate and semen are different from those in rabbit hypothalamus" J. Endocrinology, 120: 31-36

EXAMINER:		IDATE	CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.